GTI0101 (04/08/93) 
Page 17 of 35 
o Bilirubin <_ 2.5 mg/dL 
o Triglyceride < 400 mg/dl 
o ESR < 1.5 times the ULN 
3.14 Ability to give informed consent 
3.15 Normal cardiac function by history and physical exam 
3.16 Resting transcutaneous oxygen saturation > 90% on room air 
3.17 Kamofsky Performance Status J> 40 (see Appendix IV) 
3.18 If not treated with Ceredase, spleen size > 10X normal 
3.2 Exclusion Criteria 
Patients who meet any one of the following criteria will be excluded from study entry: 
3.21 Pregnant or lactating females: all patients must practice adequate birth control and 
females of child-bearing potential must have a negative serum beta-HCG 
pregnancy test within Study Days -7 to 0. 
3.22 Acute infection: any acute viral, bacterial, or fungal infection which requires 
specific therapy. Acute therapy must have been completed within 14 days prior 
to study treatment. 
3.23 Hepatitis-B surface antigen positive patients 
3.24 HIV-infected patients 
3.25 Acute medical problems such as ischemic heart or lung disease that may be 
considered an unacceptable anesthetic or operative risk 
3.26 Patients with any underlying conditions which would contraindicate therapy with 
study treatment (including allergies to reagents used in this study) 
3.27 Patients that have had total splenectomy performed and have significant marrow 
involvement as determined by MRI are excluded from receiving G-CSF and 
undergoing peripheral stem cell harvesting. 
[802] 
Recombinant DNA Research, Volume 17 
